Guangzhou Boji Medical and Biotechnological Co Ltd Working Capital to Net Assets Ratio
Guangzhou Boji Medical and Biotechnological Co Ltd working capital to net assets ratio. Guangzhou Boji Medical and Biotechnological Co Ltd (300404) has a Working Capital to Net Assets ratio of 44.0% as of March 2026. Working capital of CN¥484.56 Million (current assets of CN¥1.01 Billion minus current liabilities of CN¥524.28 Million) is measured against net assets of CN¥1.10 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible equity quality of Guangzhou Boji Medical and Biotechnologi to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Guangzhou Boji Medical and Biotechnological Co Ltd (2015–2025)
Working capital to net assets ratio of Guangzhou Boji Medical and Biotechnological Co Ltd from 2015 to 2025. This chart shows how Guangzhou Boji Medical and Biotechnological Co Ltd's Working Capital to Net Assets ratio has evolved across 11 annual periods from 2015 to 2025. As of March 2026, the ratio stands at 44.0%, reflecting working capital of CN¥484.56 Million against net assets of CN¥1.10 Billion CNY. See how many days can Guangzhou Boji Medical and Biotechnologi fund operations to measure how many days the company can operate on defensive assets alone.
Guangzhou Boji Medical and Biotechnological Co Ltd Working Capital to Net Assets Ratio by Year (2015–2025)
Guangzhou Boji Medical and Biotechnological Co Ltd working capital to net assets ratio by year from 2015 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Guangzhou Boji Medical and Biotechnological Co Ltd from 2015 to 2025, covering 11 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Guangzhou Boji Medical and Biotechnologi asset portfolio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 41.1% | CN¥435.40 Million | CN¥1.06 Billion | CN¥960.72 Million | CN¥525.33 Million | ▲ +2.9 pp |
| 2024 | 38.2% | CN¥382.76 Million | CN¥1.00 Billion | CN¥780.28 Million | CN¥397.51 Million | ▼ -8.5 pp |
| 2023 | 46.7% | CN¥457.67 Million | CN¥980.11 Million | CN¥815.18 Million | CN¥357.51 Million | ▲ +1.6 pp |
| 2022 | 45.1% | CN¥401.02 Million | CN¥888.72 Million | CN¥701.21 Million | CN¥300.19 Million | ▼ -5.6 pp |
| 2021 | 50.7% | CN¥429.26 Million | CN¥846.38 Million | CN¥700.10 Million | CN¥270.84 Million | ▲ +24.1 pp |
| 2020 | 26.6% | CN¥128.94 Million | CN¥485.00 Million | CN¥374.86 Million | CN¥245.91 Million | ▼ -0.9 pp |
| 2019 | 27.5% | CN¥125.52 Million | CN¥456.08 Million | CN¥286.43 Million | CN¥160.91 Million | ▲ +0.0 pp |
| 2018 | 27.5% | CN¥116.46 Million | CN¥423.71 Million | CN¥281.62 Million | CN¥165.16 Million | ▼ -13.4 pp |
| 2017 | 40.9% | CN¥169.28 Million | CN¥414.35 Million | CN¥321.35 Million | CN¥152.07 Million | ▼ -14.3 pp |
| 2016 | 55.1% | CN¥237.00 Million | CN¥429.84 Million | CN¥320.12 Million | CN¥83.13 Million | ▼ -20.6 pp |
| 2015 | 75.7% | CN¥327.68 Million | CN¥432.68 Million | CN¥408.94 Million | CN¥81.26 Million | — |